Child Epilepsy Center, Department of Pediatrics, University of Chieti, Chieti, Italy.
Epilepsia. 2013 Oct;54(10):1761-70. doi: 10.1111/epi.12341. Epub 2013 Aug 27.
To investigate whether patients with typical absence seizures (TAS) starting in the first 3 years of life, conformed to Panayiotopoulos's definition of childhood absence epilepsy (CAE), show different electroclinical course than those not fulfilling CAE criteria.
In this multicenter retrospective study, we choose a fixed duration follow-up of 36 months to examine the electroclinical course of epilepsy in all children with TAS starting before 3 years of age. The probands who fulfilled Panayiotopoulos's criteria for CAE were classified as having pure early onset absence epilepsy (P-EOAE), whereas those who did not as nonpure EOAE (NP-EOAE). In addition, these two groups of patients were further stratified according to the number of antiepileptic drugs taken to obtain initial seizure control (mono-, bi-, and tritherapy).
Patients with P-EOAE (n = 111) showed earlier initial seizure control (p = 0.030) and better seizure-free survival curve (p = 0.004) than those with NP-EOAE (n = 77). No mutation in SLC2A1 gene or abnormal neuroimaging was observed in P-EOAE. Among patients with NP-EOAE, those receiving tritherapy showed increased risk of structural brain abnormalities (p = 0.001) or SLC2A1 mutations (p = 0.001) but fewer myoclonic features (p = 0.031) and worse seizure-free survival curve (p = 0.047) than those treated with mono- and bitherapy. Children with NP-EOAE had 2.134 the odds of having relapse during the follow-up compare to those with P-EOAE.
Children with early onset TAS who did meet Panayiotopoulos's criteria showed a favorable course of epilepsy, whereas patients not fulfilling Panayiotopoulos's criteria showed increased risk of relapse at long-term follow-up.
探讨起病于 3 岁前的典型失神发作(TAS)患者是否符合 Panayiotopoulos 对儿童失神癫痫(CAE)的定义,其临床电特征与不符合 CAE 标准的患者是否不同。
本多中心回顾性研究选择 36 个月的固定随访期,以研究所有 3 岁前起病的 TAS 患儿的癫痫临床电特征。符合 Panayiotopoulos CAE 标准的先证者被分类为单纯早期发作失神癫痫(P-EOAE),不符合的为非单纯 EOAE(NP-EOAE)。此外,这两组患者还根据获得初始控制的抗癫痫药物数量(单药、双药和三药)进一步分层。
P-EOAE(n = 111)患者较 NP-EOAE(n = 77)患者更早达到初始控制(p = 0.030)和更好的无癫痫发作生存曲线(p = 0.004)。P-EOAE 未发现 SLC2A1 基因突变或异常神经影像学表现。在 NP-EOAE 患者中,接受三药治疗的患者出现结构性脑异常(p = 0.001)或 SLC2A1 基因突变(p = 0.001)的风险增加,但肌阵挛特征较少(p = 0.031)和无癫痫发作生存曲线较差(p = 0.047),低于接受单药和双药治疗的患者。与 P-EOAE 患者相比,NP-EOAE 患者在随访期间有 2.134 倍的复发几率。
符合 Panayiotopoulos 标准的早期 TAS 患儿具有较好的癫痫病程,而不符合 Panayiotopoulos 标准的患者在长期随访中复发风险增加。